home ver. 2.3. site index contact us

Message from the CEO
How We Work
Business Integrity
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

Message from the CEO

A Message from Chairman and CEO Fred Hassan

Fred Hassan

At Schering-Plough we are proud of what we do and of what we have accomplished in the past five years.

Our company begins with science. We seek to discover and make available new and innovative medicines for the patients and physicians who need them -- and for the veterinarians, farmers and others who care for animals.

We have made great progress since 2003 when we launched our Action Agenda. This has been our road map for building a company that can meet our goal to deliver high performance for the long term. Today, our company is pursuing a broad array of exciting growth opportunities.

The strength and diversity we built under the early years of the Action Agenda enabled us last year to acquire Organon BioSciences N.V. (OBS) of the Netherlands, beginning an important and exciting chapter in our company's transformation. With the Organon franchises, we become a world-class leader in women's health and fertility treatments. With Intervet, the animal health unit of OBS, we become one of the largest animal health organizations in the world. And the expertise and broad project base we had built in our R&D organization has been supplemented by important pipeline projects from the Organon portfolio.

Our new combined company can now do more for the patients, doctors, customers and other stakeholders who depend on us. Meanwhile, we stay resolutely committed to a culture of integrity, to doing what is right for the patients, and to driving high performance for the long term. Our vision remains constant: To earn trust, every day.

One important reason we are confident about this company's future is our people. The colleagues who drive Schering-Plough are the reason for our progress to date. And they will be the reason for our success in the future.

Sincerely,
Fred Hassan

Back to top

Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough